Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 139

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 139
---
 served as the Chief Resident at the Massachusetts
General Hospital. Following his medical-scientist training, he was an Endowed, Tenured Professor of Medicine and Molecular
Pharmacology and Chairman of the Infectious Diseases Department of Thomas Jefferson University in Philadelphia. Dr. Pomerantz is an
internationally recognized expert in HIV molecular pathogenesis and latency. He has developed ten approved infectious disease drugs
in important diseases including HIV, HCV, tuberculosis, and Clostridium difficile infection. We believe Dr. Pomerantz is qualified
to serve on our board of directors because of his significant scientific, executive and board leadership experience in drug
development and in the pharmaceutical industry.

Hila
Karah has served on our board since July 2021 and previously served as a member of Intec Israel’s board of directors since
December 2009 until the Merger. Ms. Karah is a managing Partner of Pitango HealthTech VC and an experienced board director. Prior to
Pitango she served as an independent business consultant to private and public companies on strategy, operations, financing, regulatory
and corporate governance. From 2006 until 2013, Ms. Karah was the chief investment officer of Eurotrust Ltd., a family office, where
she focused primarily on investments in life science, internet and high-tech companies. Prior to joining Eurotrust, Ms. Karah served
as a senior analyst at Perceptive Life Sciences Ltd., a New York-based life healthcare focused hedge fund. Prior to her position at Perceptive,
Ms. Karah was a research analyst at Oracle Partners Ltd., a healthcare-focused hedge fund based in Connecticut. Ms. Karah has served
on the board of Cyren Ltd., a cyber security company (Nasdaq, TASE: CYRN), since 2008 and the board of Dario Health Corp. (Nasdaq: DRIO)
since 2014. She also serves on the board of several private companies. Ms. Karah has a BA in molecular and cell biology from the University
of California, Berkeley, and has studied at the UCSB – UCSF Joint Medical Program. We believe Ms. Karah is qualified to serve on
our board of directors because of her longstanding service with Intec Israel, her investment career in life science companies, her scientific
background and experience serving on public company boards.

74

Anthony
J. Maddaluna has served on our board since July 2021 and previously served on Intec Israel’s board